{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:50:15Z","timestamp":1785322215824,"version":"3.55.0"},"reference-count":63,"publisher":"Informa UK Limited","issue":"8","funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009399","name":"Macular Disease Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Experimental Optometry"],"published-print":{"date-parts":[[2024,11,16]]},"DOI":"10.1080\/08164622.2024.2361752","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:18:05Z","timestamp":1717546685000},"page":"779-787","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Emerging treatments for geographic atrophy and the impact on clinical management of age-related macular degeneration"],"prefix":"10.1080","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1432-8977","authenticated-orcid":false,"given":"Carla J","family":"Abbott","sequence":"first","affiliation":[{"name":"Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia"},{"name":"Department of Surgery (Ophthalmology), University of Melbourne, East Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"Robyn H","family":"Guymer","sequence":"additional","affiliation":[{"name":"Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia"},{"name":"Department of Surgery (Ophthalmology), University of Melbourne, East Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00265-2"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02609-5"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.09.027"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.4182"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420971982"},{"key":"e_1_3_2_7_1","unstructured":"FDA approves SYFOVRETM (pegcetacoplan injection) as the first and only treatment for geographic atrophy (GA) a leading cause of blindness. Apellis. 2023 [accessed 2023 Feb 17]. https:\/\/investors.apellis.com\/news-releases\/news-release-details\/fda-approves-syfovretm-pegcetacoplan-injection-first-and-only."},{"key":"e_1_3_2_8_1","unstructured":"Iveric Bio Announces FDA Accepts New Drug Application and Grants Priority Review for Avacincaptad Pegol for the Treatment of Geographic Atrophy. Iveric Bio. 2023 [accessed 2023 Sep 1]. https:\/\/investors.ivericbio.com\/news-releases\/news-release-details\/iveric-bio-announces-fda-accepts-new-drug-application-and-grants."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14294"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-301109"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.08.022"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001392"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.07.011"},{"key":"e_1_3_2_14_1","first-page":"1500","article-title":"Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies","volume":"63","author":"Goldberg R","year":"2022","unstructured":"Goldberg R, Heier JS, Wykoff CC et al. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12-month results from the phase 3 OAKS and DERBY studies. Invest Ophthalmol Vis Sci 2022; 63: 1500\u20131500.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01520-9"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2276759"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02548-2"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01583-0"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.007"},{"key":"e_1_3_2_20_1","unstructured":"Runner M Warminski J. Treating GA: today and tomorrow. Retina today. 2023 Nov\/Dec. https:\/\/retinatoday.com\/articles\/2023-nov-dec\/treating-ga-today-and-tomorrow."},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1369042"},{"key":"e_1_3_2_22_1","volume-title":"2023 American Academy of Ophthalmology Annual Meeting","author":"Lally D","year":"2023","unstructured":"Lally D Treatment of geographic atrophy secondary to age-related macular degeneration with intravitreal ANX007, a selective classical complement inhibitor: Results of teh ARCHER study. In: 2023 American Academy of Ophthalmology Annual Meeting; 2023. San Francisco, California, USA."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.000000000020348"},{"key":"e_1_3_2_24_1","unstructured":"NGM bio announces topline results from the CATALINA phase 2 trial of NGM621 in patients with geographic atrophy (GA) secondary to age-related macular degeneration. 2022 [accessed 2023 Dec 19]. https:\/\/ir.ngmbio.com\/news-releases\/news-release-details\/ngm-bio-announces-topline-results-catalina-phase-2-trial-ngm621."},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.044"},{"key":"e_1_3_2_26_1","first-page":"1116","article-title":"Generation and characterization of CLG561: a fully-human, anti-properdin Fab for the treatment of age-related macular degeneration","volume":"57","author":"Johnson L","year":"2016","unstructured":"Johnson L, Splawski I, Baker L et al. Generation and characterization of CLG561: a fully-human, anti-properdin Fab for the treatment of age-related macular degeneration. Invest Ophthalmol Vis Sci 2016; 57: 1116\u20131116.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.1544"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2023.2267179"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20210528-05"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002632"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00471-y"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2018.03.006"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000838"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.03.059"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318265801d"},{"key":"e_1_3_2_36_1","first-page":"2263","article-title":"Early termination of a Phase 2 study of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration","volume":"64","author":"Holekamp NM","year":"2023","unstructured":"Holekamp NM, Ma L, Brunstein F et al. Early termination of a Phase 2 study of FHTR2163 in patients with geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2023; 64: 2263\u20132263.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_37_1","first-page":"1651","article-title":"A phase 2 study of encapsulated CNTF-secreting cell implant (NT-501) in patients with geographic atrophy associated with dry AMD","volume":"52","author":"Jaffe GJ","year":"2011","unstructured":"Jaffe GJ, Duncan JL, Tao W et al. A phase 2 study of encapsulated CNTF-secreting cell implant (NT-501) in patients with geographic atrophy associated with dry AMD. Invest Ophthalmol Vis Sci 2011; 52: 1651\u20131651.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.08.024"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5637"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2023.03.001"},{"key":"e_1_3_2_41_1","first-page":"2261","article-title":"Elamipretide-mediated visual function improvements are associated with ellipsoid zone integrity in patients with geographic atrophy","volume":"64","author":"Lally D","year":"2023","unstructured":"Lally D, Abbruscato A, Yordi S et al. Elamipretide-mediated visual function improvements are associated with ellipsoid zone integrity in patients with geographic atrophy. Invest Ophthalmol Vis Sci 2023; 64: 2261\u20132261.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608368"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S386662"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(05)80092-X"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.9.33"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182509778"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7457"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-001-0413-3"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.036"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.027"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-7298"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.11.041"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11073"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101017"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-316004"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15480"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2013.11.001"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v16i3.9439"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14304"},{"key":"e_1_3_2_61_1","unstructured":"RANZCO referral pathway for AMD management. 2024 [accessed 2024 April 27]. https:\/\/ranzco.edu\/policies_and_guideli\/ranzco-referral-pathway-for-amd-management\/."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.12964"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00807-9"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.14.13"}],"container-title":["Clinical and Experimental Optometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08164622.2024.2361752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T03:01:08Z","timestamp":1730343668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08164622.2024.2361752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11,16]]}},"alternative-id":["10.1080\/08164622.2024.2361752"],"URL":"https:\/\/doi.org\/10.1080\/08164622.2024.2361752","relation":{},"ISSN":["0816-4622","1444-0938"],"issn-type":[{"value":"0816-4622","type":"print"},{"value":"1444-0938","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tceo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tceo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}